Apellis Pharmaceuticals Reaches Analyst Target Price
May 08, 2023 at 07:26 AM EDT
In recent trading, shares of Apellis Pharmaceuticals Inc (APLS) have crossed above the average analyst 12-month target price of $91.28, changing hands for $93.18/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..